Search

Xencor Inc

Abierto

SectorSanidad

29.8 2.69

Resumen

Variación precio

24h

Actual

Mínimo

28.16

Máximo

31.79

Métricas clave

By Trading Economics

Ingresos

107M

-22M

Ventas

47M

51M

BPA

-0.29

Margen de beneficios

-42.422

Empleados

260

EBITDA

109M

-12M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+16.86% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

286M

1.7B

Apertura anterior

27.11

Cierre anterior

29.8

Xencor Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 oct 2026, 23:06 UTC

Xencor Inc shares are trading modestly higher in after-market hours, remaining significantly above their 20-day moving average amid improved economic activity signals.

23 oct 2026, 20:02 UTC

Xencor Inc shares fell sharply, reaching a significant low mid-morning before a slight rebound, continuing a downward trend since Thursday.

22 oct 2026, 20:07 UTC

Xencor Inc shares advanced, finishing stronger and marking the fifth consecutive day of gains, despite some retracement earlier in the session.

21 oct 2026, 21:01 UTC

Xencor Inc is advancing in after-market trading, reaching its highest cumulative return of the day and significantly above its 20-day moving average.

20 oct 2026, 20:02 UTC

Event

Xencor Inc will host a webcast on October 26 to discuss Phase 1 Study results of XmAb819 for advanced clear cell renal cell carcinoma.

19 oct 2026, 20:07 UTC

News
Event
Social Media

Xencor Inc will host a webcast on October 26 to discuss Phase 1 study results of XmAb819 ahead of the ESMO Congress presentation.

16 oct 2026, 20:07 UTC

Correlated Moves

Xencor Inc shares are declining amid a broader downturn in the biotechnology sector, with the SPDR S&P Biotech ETF (XBI) also lower due to negative analyst commentary.

15 oct 2026, 19:26 UTC

Correlated Moves

Xencor Inc shares are advancing, supported by gains in the SPDR S&P Biotech ETF following analyst upgrades and positive news from Recursion Pharmaceuticals.

14 oct 2026, 22:26 UTC

Xencor Inc shares are trading modestly lower in after-market hours, continuing a downward trend and currently about 5.70% below their 20-day moving average.

13 oct 2026, 20:01 UTC

Xencor Inc shares fell sharply, diverging from recent higher daily closes, amid unusually high trading volume today.

9 oct 2026, 20:06 UTC

Correlated Moves

Xencor Inc shares are higher, reflecting broader market gains, as the SPDR S&P Biotech ETF rises on news of Moderna's cancer vaccine partnership.

8 oct 2026, 20:07 UTC

Xencor Inc shares are modestly higher as the broader market recovers from an earlier low, showing a cumulative return of nearly 0.93%.

6 oct 2026, 20:02 UTC

Correlated Moves

Xencor Inc shares fell sharply, influenced by the declining SPDR S&P Biotech ETF amid concerns over inflation risks and dilution from public offerings.

2 oct 2026, 19:55 UTC

Xencor Inc shares fell, continuing a four-session decline, after peaking early in the day amid broader weakness in the biotechnology sector.

30 sept 2026, 20:07 UTC

News

Shares of Xencor Inc. fell sharply despite Wells Fargo initiating coverage with an Overweight rating and a $55.00 price target.

29 sept 2026, 19:46 UTC

Xencor Inc shares fell sharply, showing unusual volatility and dipping nearly 4% since Monday's close before recovering slightly.

28 sept 2026, 20:02 UTC

News

Truist Securities raised its price target on Xencor Inc to $29.00, as the stock experiences unusually high volume and continues to gain sharply.

24 sept 2026, 19:46 UTC

Xencor Inc shares fell sharply, continuing a downward trend since Wednesday and remaining significantly below its 20-day moving average amid broader market weakness.

23 sept 2026, 20:07 UTC

Correlated Moves

Xencor Inc shares fell sharply, reflecting a broader decline linked to significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

22 sept 2026, 19:45 UTC

Xencor Inc is modestly higher, continuing positive momentum after four consecutive sessions of gains, despite remaining below its 20-day moving average.

21 sept 2026, 20:31 UTC

Xencor Inc. has risen in after-market trading, recovering from an initial dip and reaching a peak notably higher than Monday's close.

17 sept 2026, 20:07 UTC

Correlated Moves

Xencor Inc is advancing, likely supported by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

16 sept 2026, 19:16 UTC

Xencor Inc is trading roughly flat, having fluctuated within a typical range but remains significantly below its 20-day moving average.

15 sept 2026, 23:16 UTC

Shares of Xencor Inc. are lower in after-market hours amid broader market pressures and rising yields on the ten-year Treasury note.

10 sept 2026, 20:07 UTC

Xencor Inc's shares are lower today, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

8 sept 2026, 20:07 UTC

Xencor Inc shares are trading lower today, following a notable early decline and remaining below their 20-day moving average. No specific news was identified.

4 sept 2026, 20:07 UTC

Xencor Inc shares are higher, recovering from earlier losses amid broader market selling pressure following a strong jobs report. No specific news was identified.

3 sept 2026, 22:15 UTC

News

Shares lower in after-market trading after JP Morgan's rating.

2 sept 2026, 20:08 UTC

Xencor Inc shares are lower today, reversing from an early gain amid a weaker-than-expected ADP employment report affecting investor sentiment on interest rates.

1 sept 2026, 23:01 UTC

Xencor Inc shares are lower in after-market hours, with no specific news identified. This decline occurs amid broader market concerns over economic growth data.

Comparación entre iguales

Cambio de precio

Xencor Inc previsión

Precio Objetivo

By TipRanks

16.86% repunte

Estimación a 12 Meses

Media 34.1 USD  16.86%

Máximo 46 USD

Mínimo 20 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xencor Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

11

Comprar

2

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat